

VPA22622/023/001

**Vetoryl 10 mg hard capsules for dogs**

<b>Variation</b>	<b>Summary</b>	<b>Date</b>
Vet - B43	VNRA - Vet - B43 - - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	02/03/26
Vet - B12 b)	VNRA - Vet - B12 b) - - Vet - B12 b) - Minor changes: - to an approved test procedure — for the immediate packaging of the active substance or the finished product	31/10/25
Vet - B28 a)	VNRA - Vet - B28 a) - - Vet - B28 a) - Change in the specification parameters or limits of an excipient tightening of specification limits	31/10/25
Vet - F.V.b 1. c)	VRA-S - Vet - F.V.b 1. c) - - Vet - F.V.b 1. c) - Harmonisation of the quality dossier Harmonisation of the quality dossier for the same purely national products and/or the same products approved in MR/DC procedures which are owned by the same MAH not participating in a former union interest referral procedure or SPC harmonisation procedure	10/09/25
Vet - F.III.1 b) z.	VRA-R - Vet - F.III.1 b) z. - b) European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient z. Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 b) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	12/05/25
Vet - F.III.1 b) z.	VRA-R - Vet - F.III.1 b) z. - b) European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient z. Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 b) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	12/05/25
Vet - F.III.1 b) z.	VRA-R - Vet - F.III.1 b) z. - b) European Pharmacopoeial TSE	12/05/25

	<p>Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient z. Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 b) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance</p>	
Vet - B43	<p>VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible</p>	17/04/25
Vet - B3 d)	<p>VNRA - Vet - B3 d) - d) Deletion of a non-significant specification parameter (active substance, starting material, intermediate - B3 d) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) of — an active substance; — a starting material; —an intermediate or reagent used in the manufacturing process of the active substance</p>	17/04/25
Vet - B11 d)	<p>VNRA - Vet - B11 d) - d) Addition of a new specification parameter to the specification with its corresponding test method - B11 d) Changes to the quality part of the dossier: Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance —addition of a new specification parameter to the specification with its corresponding test method</p>	17/04/25
Vet - B3 e)	<p>VNRA - Vet - B3 e) - e) Deletion of a test procedure - B3 e) Changes to the quality part of the dossier: Deletion of a test procedure — for the active substance or a starting material, reagent or intermediate of the active substance; —for the immediate packaging of the active substance; — for an excipient or the finished product; —for the immediate packaging of the finished product</p>	17/04/25
Vet - F.I.f.1	<p>VRA-S - Vet - F.I.f.1 - 1. Substantial changes in the updated version of the ASMF or the active substance part of the dossier - F.I.f.1 Quality Changes - Active Substance - Other changes to the active substance - Substantial changes in the updated version of the ASMF or the active substance part of the dossier</p>	26/03/25
Vet - F.III.1 a) z.	<p>VRA-R - Vet - F.III.1 a) z. - a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 a) z.</p>	13/03/25

	Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - B40	VNRA - Vet - B40 - Replacement or addition of a supplier of packaging components or devices - B40 Changes to the quality part of the dossier: Replacement or addition of a supplier of packaging components or devices (when mentioned in the dossier)	02/09/24
Vet - B11 d)	VNRA - Vet - B11 d) - d) Addition of a new specification parameter to the specification with its corresponding test method - B11 d) Changes to the quality part of the dossier: Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance —addition of a new specification parameter to the specification with its corresponding test method	02/09/24
Vet - B12 c)	VNRA - Vet - B12 c) - c) Minor changes to an approved test procedure for an in-process test - B12 c) Changes to the quality part of the dossier: Minor changes — to an approved test procedure for an in-process test — for active substance; — for the finished product	02/09/24
Vet - B40	VNRA - Vet - B40 - Replacement or addition of a supplier of packaging components or devices - B40 Changes to the quality part of the dossier: Replacement or addition of a supplier of packaging components or devices (when mentioned in the dossier)	02/09/24
Vet - B40	VNRA - Vet - B40 - Replacement or addition of a supplier of packaging components or devices - B40 Changes to the quality part of the dossier: Replacement or addition of a supplier of packaging components or devices (when mentioned in the dossier)	02/09/24
Vet - B40	VNRA - Vet - B40 - Replacement or addition of a supplier of packaging components or devices - B40 Changes to the quality part of the dossier: Replacement or addition of a supplier of packaging components or devices (when mentioned in the dossier)	02/09/24
Vet - B31	VNRA - Vet - B31 - Uniformity of dosage units is introduced to replace the currently registered method - B31 Changes to the quality part of the dossier: Uniformity of dosage units is introduced to replace the currently registered method	29/08/24
Vet - B3 n)	VNRA - Vet - B3 n) - n) Deletion of a non-significant specification parameter (finished product) - B3 n) Changes to the quality part of the dossier: Deletion of a non-significant	28/08/24

	specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) in the specification parameters or limits of the finished product	
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuring device) - B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; —for the immediate packaging of the active substance or the finished product; — of a measuring or administration device	28/08/24
Vet - F.II.d.1 b)	VRA-S - Vet - F.II.d.1 b) - b) Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product - F.II.d.1 b) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product	27/08/24
Vet - F.II.d.1 b)	VRA-S - Vet - F.II.d.1 b) - b) Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product - F.II.d.1 b) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product	27/08/24
Vet - F.II.d.1 b)	VRA-S - Vet - F.II.d.1 b) - b) Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product - F.II.d.1 b) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product	27/08/24
Vet - F.II.d.1 a)	VRA-S - Vet - F.II.d.1 a) - a) Change outside the approved specifications limits range - F.II.d.1 a) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	27/08/24
Vet - F.II.d.1 a)	VRA-S - Vet - F.II.d.1 a) - a) Change outside the approved specifications limits range - F.II.d.1 a) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	27/08/24
Vet - F.V.b 1. c)	VRA-S - Vet - F.V.b 1. c) - c) Harmonisation of the quality dossier for the same purely national products and/or the same products approved in MR/DC procedures which are owned by the same MAH not participating in a former union interest referral procedure or SPC harmonisation procedure - F.V.b 1. c) Quality Changes - Changes to a marketing authorisation resulting from other regulatory procedures - Harmonisation of the quality dossier - Harmonisation of the quality dossier for	27/08/24

	the same purely national products and/or the same products approved in MR/DC procedures which are owned by the same MAH not participating in a former union interest referral procedure or SPC harmonisation procedure	
Vet - G.I.19	VRA-R - Vet - G.I.19 - G.I.19 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet to implement the outcome of the MAH's signal management process according to Article 81(2) of Regulation (EU) 2019/6 - G.I.19 - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet to implement the outcome of the MAH's signal management process according to Article 81(2) of Regulation (EU) 2019/6	26/06/24
Vet - G.I.4	VRA-S - Vet - G.I.4 - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data. - G.I.4 Safety, Efficacy, Pharmacovigilance changes - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data.	26/06/24
Vet - F.I.a.2 z)	VRA-R - Vet - F.I.a.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.a.2 z) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	05/06/24
Vet - B34	VNRA - Vet - B34 - Change in qualitative and quantitative composition of the immediate packaging for a solid pharmaceutical form for a finished product - B34 Changes to the quality part of the dossier: Change in qualitative and quantitative composition of the immediate packaging for a solid pharmaceutical form for a finished product	02/01/24
Vet - A1 b)	VNRA - Vet - A1 b) - b) Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier. - A1 b) Administratvie changes: Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier.	20/12/23
Vet - B3 d)	VNRA - Vet - B3 d) - d) Deletion of a non-significant specification parameter (active substance, starting material, intermediate - B3 d) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g.	20/12/23

	deletion of an obsolete parameter) of — an active substance; — a starting material; — an intermediate or reagent used in the manufacturing process of the active substance	
Vet - B3 e)	VNRA - Vet - B3 e) - e) Deletion of a test procedure - B3 e) Changes to the quality part of the dossier: Deletion of a test procedure — for the active substance or a starting material, reagent or intermediate of the active substance; —for the immediate packaging of the active substance; — for an excipient or the finished product; —for the immediate packaging of the finished product	20/12/23
Vet - B43	VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	20/12/23
Vet - B47 b)	VNRA - Vet - B47 b) - b) Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - B47 b) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: — change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	20/12/23
Vet - B3 n)	VNRA - Vet - B3 n) - n) Deletion of a non-significant specification parameter (finished product) - B3 n) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) in the specification parameters or limits of the finished product	30/08/23
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	03/08/23
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuring device) - B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; —for the immediate packaging of the active substance or the finished product; — of	01/08/23

	a measuring or administration device	
Vet - B3 k)	VNRA - Vet - B3 k) - k) Deletion of a non-significant in-process test (finished product manufacture) - B3 k) Changes to the quality part of the dossier: Deletion of a non-significant in-process test (e.g. deletion of an obsolete test) during the manufacture of the finished product	21/12/22
Vet - B43	VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	16/12/22
B.II.b.5.c	IA - B.II.b.5.c - c) Deletion of a non-significant in-process test - B.II.b.5.c - QUALITY CHANGES - FINISHED PRODUCT - Manufacture - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test	07/03/22